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 With advances in drug research, the use of biological therapeutics is becoming a 
reality.  Unfortunately, methods for processing and delivering these fragile 
macromolecules often limit their therapeutic potential.  For this dissertation, we explore 
the aerosolization of macromolecules by way of electrohydrodynamic atomization 
(EHDA) and how this method can be used to process and deliver therapeutics.  EHDA 
employs a high voltage to break a column of liquid into drops.  It was unknown if or how 
the residual charge left of the resulting droplets would affect lung cells.  An in vitro 
experiment was conducted to spray aerosolized DNA, by way of EHDA, onto human 
derived lungs cells to test for immunogenic and toxic effects.  The lung cells displayed no 
immunogenic or toxic response to the DNA or high voltage.  Previous researchers have 
used EHDA to aerosolize proteins with mixed results.  This work sets forth a simplified 
thermodynamic theory and provides recommendations to pharmaceutical companies on 
how to design more stable protein formulations for aerosol processing or delivery.  
Finally, a new method of producing liposomes was created.  It constructs the liposome 
one layer at a time.  The inside of the liposome is sprayed by EHDA, with the lipid and 
drug in solution together.  As the sprayed monolayer passes through a pool containing a 
solution of lipid in water, the second part of the bilayer attaches to the inner layer 
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Significant progress has been made toward uncovering cellular pathways that 
cause disease and illness.  In response, many potential cures or treatments focus on using 
biological macromolecules as therapeutics (such as DNA, RNA, or proteins).  These 
macromolecules can be extremely fragile and exceedingly expensive.  As a result, many 
methods used for delivering small molecule therapeutics are not suitable for all 
macromolecules.  One noninvasive method for delivering these molecules to the body is 
via inhalation, which has the added benefit of avoiding the first pass metabolism.  
Electrohydrodynamic atomization (EHDA) is a technique that has recently been 
introduced to the field of pharmacology.  Through the process of atomization, liquids are 
turned into to small mono-disperse drops that can be inhaled.  Although there is some 
literature examining EHDA and its use in pharmaceutical delivery, there are many 
questions that need to be addressed before this technique can be ready for commercial 
use.  For example: 
 Will the residual charge on the resulting droplets exasperate compromised 
tissue? 
 Does the EHDA protect proteins like it appears to protect plasmid DNA? 
 Can the laminar flow of the EHDA system be manipulated to add 
additional benefits over traditional aerosolization techniques, i.e., can we 
make liposomes on demand? 
 
2 
1.1 Macromolecule Fragility 
 Biological molecules are of increasing interest to the pharmaceutical industry due 
to their high specificity.  They can target or interact with very specific molecules leading 
to fewer possible side effects and higher efficacy.  In addition, integrating therapeutic 
DNA into the cell has the potential to cure genetic diseases.  DNA, RNA, and proteins 
are known as macromolecules because of their large molecular weight that can range 
from a few thousand to many million Daltons.  Due to their large size and structure-
dependant weak hydrogen bonding, these molecules can be easily degraded both 
physically and chemically during manufacture or delivery.  Therefore, it is imperative 
that the macromolecules be protected and stabilized as much as possible. 
 
1.2 Electrohydrodynamic Atomization 
EHDA is a technique that applies a high voltage to a liquid exiting a small 
capillary tube.  The resulting electrical field, between the capillary and the ground ring, 
generates a potential force on the fluid column that is aligned with the axial direction of 
the capillary tube.  When this electrical potential is sufficiently large to dominate the 
fluid dynamics of the jet or large enough to overcome 
surface tension forces in the liquid, classical dripping 
modes of jet breakup are transformed into thin threads of 
liquid jets emanating from the liquid-gas interface.  It is 
believed classical Rayleigh breakup drives the division of 
these thin filaments into droplets.  Unless neutralized, these 
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tiny droplets retain a residual charge from the process and are attracted to any oppositely 
charged surface.   
Figure 1.1 - Diagram of EHDA 
 
The EHD spray is capable of producing drops ranging from fractions of 
millimeters down to nanometers [1]. It is currently used in a variety of different industries 
such as:  combustion, paint and coating applications, propulsion, agricultural pesticide 
application, chemical composition in mass spectrometry, and, most recently, drug 
delivery.  As the liquid leaves the nozzle, the shape of the liquid jet and its behavior (also 
known as “mode”) is dependent upon: the liquid’s properties, the flow rate of the liquid, 
and the applied voltage [2, 3].  The most stable shape that produces the uniform drop size 
is known as the Taylor cone and was first described by Sir Geoffrey Ingram Taylor in 
1964 [4].  The properties that influence drop size have been debated throughout the years.  
Recently, Ganan-Calvo et al. discovered a relationship between drop size and the Weber 
number (Equation 1) [5].  The important properties that determine the radius of the drop 
(Rd) are: density (ρ), flow rate (Q), radius of the jet (R), surface tension (σ), permittivity 
of vacuum (εo), and electrical conductivity (K).  To solve for the radius of the drop, three 
intermediate parameters must be solved for include the Weber number (We), pressure 
difference (ΔP), and jet radius (Rσ). 
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Equation 1.1 - From Ganan-Calvo et al.[5], the equations below determine the size of a 

























1.3 Using EHDA for DNA atomization 
 There are many different devices available for atomizing macromolecular 
therapeutics.  FDA approved delivery devices include jet nebulizers, ultrasonic 
nebulizers, metered-dose inhalers (MDI), and dry powder inhalers (DPI).  These devices 
have many drawbacks including creating polydisperse drops that are ingested rather than 
deposited in the lungs, drug deposition dependency on patient inspiration rate, high waste 
or residual volume, and overall poor drug deposition in the lungs (less than 50% for 
nebulizers, less than 25% for MDI, and less than 17% for DPI) [6, 7].  This has sparked a 
need for new drug atomization methods.  EHDA avoids some of the shortcomings of the 
other aerosol techniques.  It creates monodisperse drops one at a time minimizing the 
residual volume of drug in the device.  Since the size of the drop can easily be 
manipulated, it can be tailored to the best possible size for lung deposition.  Finally, 
studies have been conducted atomizing plasmid DNA that concluded that EHDA was the 
most effective and structurally safest way to atomize DNA [8]. 
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 Although DNA retains structural integrity during atomization with EHDA, an 
unanswered question still remains.  Will these highly charged drops affect cells?  The 
study in Chapter 2 was designed to answer this question by assessing toxicity, 
inflammatory response, and transfection efficiency of naked and complexed plasmid 
DNA delivered via EHDA to normal human bronchial/tracheal epithelial cells in vitro. 
 
1.4 Protein Stability During Atomization 
Although proteins are significantly smaller in size than DNA, proteins can pose a 
potentially more complicated problem in terms of drug delivery.  Proteins have tertiary 
and quaternary structures that are vital for stability and function.  Early observations by 
Maa et al. [9] associated protein stability with surface area to volume ratios.  They noted 
a linear relationship between droplet diameter and protein aggregation.  In addition, they 
believed that over time more protein would be drawn to the interface of the drop causing 
greater protein denaturation and aggregation, hence stating that degradation is a time 
dependant process.  As a result, we wondered if the residual charge on an EHDA droplet 
could be used to push proteins off the interface into the bulk solution slowing the time 
dependent degradation process.  
There are few published works using EHDA to atomize proteins [10-12].  
Moreover, the results from such studies are conflicting.  Some proteins retain 100% 
activity after spraying, while others lose activity depending on flow rates or 
concentration.  The cause for these discrepancies is currently unknown.  Attempts to 
correlate protein properties that could affect stability such as:  size, isoelectric point, type 
of protein, buffer pH, melting temperature, and percent hydrophobic provided little 
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insight into to the problem.  However, crude studies in our lab using a static droplet show 
no time dependant degradation behavior, putting into question Maa’s original hypothesis.  
Randolph et al. expanded on Maa’s original theory stating that in order for a protein to 
remain stable, its change in surface tension divided by the change in surface area must be 
greater than zero, else the protein unfolds [13]. This statement removes time dependence 
by removing the concept that the protein must be at the interface to unfold.  Delving 
further into these observations, melting enthalpy is directly correlated to melting 
temperature and surface tension multiplied by surface area.  Enthaply is an energy; this 
understanding led to the thought that protein stability during EHDA is a thermodynamic 
issue.  Based on this, Chapter 3 will explore the idea that the energy input into the system 
necessary to create the aerosol must be less than the energy within the protein in order for 
the molecule to remain in its native state.  Our goal for this chapter is to develop a 
universal transition criterion for protein stability during aerosolization based on three 
easily measurable quantities: surface tension, droplet diameter, and melting enthalpy.  As 
such, protein engineers can manipulate formulation to sustain activity using a clear 
engineering method rather than the current trial and error process. 
 
1.5 Liposome Encapsulation 
One modern approach to adding efficacy to therapeutic drugs is by enhancing 
protection and targeting through encapsulation.  Encapsulation for drug delivery consists 
of a protective coating on the surface of the drop that is typically composed of 
biocompatible polymers or lipids.  Current methods of encapsulation include double 
emulsion, solvent evaporation/extraction technique, swelling, extrusion, electroformation, 
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electroinjection, and spray drying.  However, these techniques typically suffer from low 
encapsulation efficiencies and polydisperse size distribution.  In addition, these methods 
are not always capable of fully encapsulating the drug, i.e. a small section from a large 
molecule can protrude outside the shell.   
The laminar flow field inherent to the EHDA process makes it ideal for 
encapsulation processes whereby one material can be co-extruded concentrically over the 
other [14, 15].  However, the EHDA process can be used for encapsulation in another 
way.  The small droplet diameters of the process also make it ideal for developing less 
complicated and more reliable strategies using miscible fluids and molecular diffusion to 
self-assemble the protective layer on the liquid-gas interface.   
EHDA is used as a single step encapsulation process that can be divided into two 
critical stages.  The first stage includes spraying the encapsulation solution that contains 
the macromolecule and lipid.  As the droplet falls towards a catch basin, the hydrophobic 
tails of the lipid molecules will be drawn to the liquid-gas interface of the drop due to 
their inherent attraction to hydrophobic/hydrophilic interfaces.  The lipids on the surface 
will have their hydrophobic tails pointing outward of the drop.  The second stage occurs 
when the drop comes into contact with the catch pool.  The catch pool is comprised of an 
aqueous solution with lipids floating on the surface.  As the drop passes into the pool, the 
lipid layer of the drop pairs with the lipid layer of the surface of the pool creating a 
bilayer.  The drop then travels deeper into the pool where the bilayer pinches off, creating 
a liposome.  The critical parameters necessary for the success of this technique include 
the density and solubility of the lipid in the sprayed solution.  Chapter 4 is focused on 
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using dense salt solutions that are miscible with lipid-isopropanol mixtures as the spray 
solution in order to create stable liposomes. 
 
1.6 Summary of Aims 
The three aims of this research project are to provide a better understanding of 
EHDA and its possible use in therapeutic drug delivery.  Each of these aims build upon 
one another and need to be addressed before EHDA can be used safely and effectively in 
the pharmaceutical industry.  The following chapters will explore in depth each of the 
topics in turn.  Each chapter is presented as an individual, stand alone paper with the 




































Interest in utilizing DNA-based pharmaceuticals to treat pulmonary diseases such 
as acute respiratory distress syndrome (ARDS), cancer, asthma, emphysema, and cystic 
fibrosis has increased in recent years [16-21].  In fact, approximately 8% of all current 
clinical trials worldwide focus on treating pulmonary diseases 
(http://www.clinicaltrials.gov).  Delivery to this region of the body can be undertaken by 
three distinct routes: direct injection, systemic delivery through intravenous injection, or 
topical administration by instillation or aerosolization [17].  Of these three methods, 
topical administration, specifically aerosolization, is the most popular option due to its 
ability to directly and non-invasively target the diseased airway cells as well as reducing 
toxic effects on other organs in the body [22]. Unfortunately, poor in vivo results were 
encountered when naked plasmid DNA ranging in size from 4.7 to 7.2 kilobase pairs 
(kbp) was delivered with the two most clinically utilized atomization devices:  jet and 
ultrasonic nebulizers [23, 24].  It has been suggested that loss in DNA molecular 
integrity, as a direct result of the aerosolization process, may be responsible for these 
poor results [23-32].  Under these circumstances, a decrease in molecular integrity would 
be manifested as a strand break in the plasmid DNA resulting in the transition of the 
native supercoiled conformation into an open circle form.  Subsequent strand breaks at 
the same location on the opposite strand of the plasmid would result in a double strand 
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break and conversion of the open circle form to a linear structure.  Additional double 
strand breaks then reduce the full-length linear molecule into smaller sized fragments 
(i.e., ‘fragmented DNA’).  To achieve robust gene expression, either the supercoiled or 
open circle form of plasmid DNA must be preserved [33].   
Studies to improve the delivery and expression of non-viral gene therapies via 
aerosolization are focused in two primary areas.  First, in order to improve tidal volume 
and breathing frequency, carbon dioxide has been incorporated into the surrounding 
environment [25, 34].  While this method demonstrated a significant increase in 
therapeutic expression, it is not clinically desirable.  Second, cationic lipids (e.g., 1,2-
dioleoyl-3-trimethylammonium propane; DOTAP) and polymers (e.g., 
polyethyleneimine; PEI, poly-L-lysine; PLL) complexed to DNA molecules increase in 
vivo transfection after aerosolization by both jet and ultrasonic nebulizers [23-32].  These 
agents have the ability to protect the DNA from nuclease degradation, decrease the 
molecule’s overall hydrodynamic diameter, and assist in transporting DNA across both 
cellular and nuclear membranes [35-41].  Unfortunately, in some cases, the cationic agent 
can fail to dissociate from the DNA molecule within the intracellular environment, 
thereby preventing gene expression [42-44].  Additionally, some investigators have 
observed an increase in immune response when DNA complexed to these agents has been 
delivered via the pulmonary route [45-50]. 
To overcome the observed loss in plasmid DNA’s molecular integrity during 
aerosolization, most investigations to date have focused on modifying the therapeutic 
formulation via the addition of complexing agents as opposed to examining the 
aerosolization method itself.  Our previous studies assessed the effects of various 
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aerosolization devices on an assortment of sizes (5 kbp to 37 kbp) of naked (non-
complexed) plasmid and cosmid DNA [51].  We found electrohydrodynamic atomization 
(EHDA) sprays to have a high potential for delivery of DNA to the lungs since damage to 
molecular integrity was minimal for all investigated DNA sizes.   
Operating at relatively low flow rates, EHDA sprays (also known as 
electrosprays) apply high voltages to a fluid overcoming the fluidic surface tension forces 
to form a fine aerosol [52].  Briefly, a potential force is created between a charged fluid, 
developed when the fluid flows through an electrically conducting capillary to which the 
voltage is applied, and a ground plate.  The generation of an aerosol occurs at the 
capillary exit.  Interestingly, a sequence of spray modes is observed that is known to be 
dependent upon a number of factors including: volumetric flow rate, applied voltage, 
setup of the device (e.g. distance between capillary and plate or capillary radius), and 
properties of the fluid (e.g., surface tension, density, electrical conductivity) [53-55].  The 
physical basis for these spray modes is not known, but the first observed mode is the 
dripping mode.  In the absence of an electric field, the liquid drips from the capillary as 
large droplets.  An increase in applied voltage results in an increase in the frequency at 
which the dripping occurs in conjunction with a decrease in droplet diameter.  The 
reduction in droplet diameter is thought to be a result of a decrease in surface tension due 
to the accumulation of charges on the fluid surface [54].  A further increase in applied 
voltage results in the next displayed mode, the cone-jet mode.  This mode consists of an 
axially stable cone meniscus from which a simple, straight linear jet with some varicose 
instability is emitted.  The cone-jet mode is perhaps the most investigated and well-
known EHDA spray mode since it produces a fine, nearly mono-disperse aerosol [56, 
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57].  Destabilization of the cone-jet mode occurs with additional increases in applied 
voltage and results in the formation of a whipping cone, followed by a multi-jet spray.  
The whipping cone mode displays an irregular meniscus from which droplets are 
produced in unpredictable directions, while the multi-jet spray consists of a flat, stable 
meniscus with multiple small cones extending from the rim of the capillary.   
Investigations exploring the use of EHDA sprays as a method for non-pulmonary 
and pulmonary delivery are limited [58-60].  To our knowledge, only one in vivo study 
examining the effects of EHDA sprays on respiratory epithelium has been undertaken 
[61].  Although this study did administer DNA to living mice using EHDA, the study 
ignored any toxic or immunologic effects and recovered very little of the starting 
material.  Since significant voltages are required to create suitably sized droplets, the 
potential harm to the respiratory epithelium by these charged droplets must be evaluated 
before EHDA sprays can be considered a viable method for delivery via the respiratory 
tract.  Also, in vitro assessment of EHDA sprays would benefit from epithelial cell 
culture models that resemble in vivo conditions as closely as possible [62]. 
In selecting a lung epithelial cell culture system for assessing the effects of 
EHDA sprays, the technique by which cells are cultured becomes critical.  Conventional 
liquid-covered culture (LCC) completely immerses the monolayer of cells in growth 
media, which does not allow direct exposure to the sprayed material.  In contrast, cells 
cultured at an air-liquid interface (ALI) are continually exposed to air and therefore, 
better simulate the in vivo situation.  These cells are grown on a semi-permeable support 
coated with collagen and are maintained with culture media from the basolateral side 
only.  ALI cultured cells have been shown to develop and retain epithelial cell features 
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including bioelectric properties, mucin secretion, and the development of cilia and tight 
junctions [63].  Additionally, cells cultured by this method are still capable of responding 
to stresses arising from the environment [64, 65].  Previous researchers have compared 
EpiAirway™ ALI cells to in vivo experiments (in humans and rats) and found that the in 
vitro permeability correlates directly to in vivo bioavailability, and that EpiAirway™ 
cells have statistically similar repair kinetics [66-68].  Utilizing commercially available 
ALI cultured bronchial/tracheal epithelial cells, we assessed the effects of delivering 
naked plasmid DNA, lipid/DNA complexes, polyethyleneimine (PEI)/DNA complexes, 
and poly L-lysine (PLL)/DNA complexes by electrospray.  Specifically, we examined 
toxicity and cytokine response as well as monitored transfection efficiency.  
 
2.2 Materials 
Luciferase plasmid DNA (5.9 kbp) was provided by Valentis, Inc. (Burlingame, 
CA); Trizma® hydrochloride (Tris-HCl), agarose, polyaspartic acid, ethidium bromide, 
and Poly L-lysine, lipopolysaccaride 055:B5 (LPS) were obtained from Sigma-Aldrich 
(St. Louis, MO); diethylenetriaminepentaacetic acid (DTPA) was purchased from Acros 
Organics (Fisher Scientific, Hampton, NH); and 5X Receptor Lysis Buffer was acquired 
from Promega Corp. (Madison, WI); 50X Tris/Acetate/EDTA (TAE) buffer came from 
Bio-Rad Laboratories (Hercules, CA).  Linear PEI (MW 25,000) was obtained from 
Polysciences, Inc. (Warrington, PA) and used in aqueous solution.  DNA was dissolved 
to a final concentration of 0.02 mg/ml in buffer (10 mM Tris-HCl, 200 µM DTPA, pH 
8.5).  The lipid, 1,2-Dioleoyl-3-Trimethylmmonium-Propane (DOTAP) was acquired 
from Avanti Polar Lipids (Alabaster, AL).  The modified PEI for low toxicity in the 
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complexes was a generous gift from Dr. Manfred Ogris of the Ludwig Maximilians 
Universitat München.  The modification of the PEI are found in detail in Russ et al. 
(2008) and described as pseudodendrimer HD O [69]. 
 
2.3 Methods 
Preparation and Analysis of DNA Complexes 
 PEI/DNA complexes were prepared at two different ratios; a 6:1 and 10:1 
nitrogen to phosphate ratio.  The 10:1 ratio was prepared by mixing 2.7 µg PEI with 2 µg 
plasmid DNA in 10 mM Tris-HCl and 200 µM DTPA buffer to a total volume of 2 ml in 
polypropylene centrifuge tubes and incubated for 10 minutes at room temperature.  The 
6:1 ratio of PEI/DNA was prepared similarly, as well as the modified PEI/DNA complex 
(also mixed at a 6:1 ratio).  The modified PEI was used in addition to the linear PEI 
because it has been previously described as less toxic [69]. 
 The PLL/DNA complexes were created at a ratio of 6:1 nitrogen to phosphate.  
After mixing, the complexes were incubated at room temperature for 15 minutes before 
use.  The lipid/DNA complexes were made using lipid mixture of 1:1 DOTAP to 
cholesterol.  A volume of 1.5 ml of 0.04 mg/ml DNA in 10 mM Tris-HCl (without 
DTPA) was added to 1.5 ml of lipid mixture (containing 0.487 mM DOTAP).  The 
mixture was incubated at room temperature for 15 minutes before spraying. 
Electrohydrodynamic Spray 
 Solutions (3 ml) containing naked DNA or any of the suspensions containing 
complexes were pumped through a stainless steel capillary tube (0.56 mm inner diameter, 
1.07 mm outer diameter) at a flow rate of 0.2 ml/min using a New Era Pump Systems 
15 
Model NE-1000 syringe pump (Wantagh, NY).  The system, with a needle-to-ground 
distance of 2.5 cm, was run at either a voltage of 0 kV or -6 kV.  A dripping profile was 
observed at an applied voltage of 0 kV while the applied voltage of -6 kV exhibited a 
stable cone-jet.  
Cell Culture 
 EpiAirwayTM tissues, cultured on collagen supports under air-liquid interface 
conditions, were obtained from MatTek Corp. (Ashland, MA; Figure 2.1).  These tissues 
consisted of normal, human derived tracheal/bronchial epithelial cells that were highly 
differentiated (e.g., cilia, tight junctions, sodium and chloride channels) and retain 
properties of normal respiratory epithelial tissue (e.g., actively secrete mucus, 
electrogenic).  The tissues had an average trans epithelial electric resistance (TEER) of 
391.2 ± 50.2 ohms/cm2.  Upon delivery, the tissue inserts were processed according to the 
supplier’s protocol.  Briefly, each tissue insert was transferred to a well in a 6-well plate 
pre-filled with 900 µl pre-warmed serum free media (AIR-100-MM, MatTek Corp.) and 
incubated at 37°C in 5% CO2 overnight (16-18 hours) prior to in vitro investigations. 
 
Figure 2.1 - Schematic of the air-liquid interface tissue technique.  The apical surface is exposed to air 
while the basolateral side absorbs nutrients from the liquid media.  Diagram used with permission of 
MatTek Corp.  All rights reserved. 
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In Vitro Investigations 
 At the end of the incubation period, each tissue insert was transferred to a well in 
a 24-well plate containing 1000 µl pre-warmed AIR-100-MM media.  A total of 100 µl 
(the supplier’s recommended maximum applied volume) containing either naked DNA or 
one of the complexes in buffer was atomized either directly onto the apical tissue surface 
for 32 seconds, or into a small cell culture dish with subsequent application to the cell 
surface.  Thus, a total of 2 µg of DNA was applied to each tissue sample.  At specific 
post-application time points from 0 to 72 hours, 1000 µl of underlying culture media was 
removed from each well and replaced with fresh, pre-warmed AIR-100-MM media.  Of 
this removed culture media, 500 µl was stored at -80°C for evaluation of cellular toxicity 
while the remaining volume was stored at -20°C for analysis of cytokine response.  A 72-
hour time study demonstrated that these storage conditions sustained LDH and IL-8 
levels comparable to fresh controls.  The reported values for cellular toxicity and 
cytokine response are cumulative for each time point.  Control conditions included the 
incubation of cells in AIR-100 MM media (untreated); cell exposure to the maximum 
electric field of 2.8 kV/cm (electric field); treatment with plasmid DNA or PEI/DNA 
complexes that had not been processed through the EHDA spray system (pipette); 
applying the Tris-HCl buffer (without DNA) directly onto the cells using the EHDA 
spray system at two different voltages (spray buffer); and treatment of LPS (positive 
control).  ‘Untreated’ tissues were not exposed to an electric field nor were they subjected 
to DNA application.  To expose the tissues to the maximum electric field, the tissue 
inserts were placed between a dry capillary tip and ground for a total of 32 seconds at a 
maximum voltage of -7 kV.  Controls for the unprocessed DNA, liposome/DNA, and 
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PEI/DNA complexes were done by pipetting 100 µl of the desired DNA solution directly 
on top of the tissue.  The LPS was used as a positive control because it is known to elicit 
an IL-8 response in EpiAirway™ cells (as per supplier recommendation).  One hundred 
microliters of 0.1 µg/µl LPS solution was pipetted directly on top of the cells.  All of the 
tissues were maintained at 37°C in 5% CO2 between time points. 
Evaluation of Cellular Toxicity 
Lactate dehydrogenase (LDH) levels in culture medium were measured using the 
CytoTox 96 Cytoxicity Assay Kit (Promega Corp., Madison, WI) following the 
manufacturer’s protocol.  Released LDH in culture medium was measured with a 30-
minute coupled enzymatic assay, which converted 2-p-iodophenyl-3-p-nitrophenyl-5-
phenyl tetrazolium chloride (INT) into a red formazan product that could be detected 
with UV spectrophotometry.  Briefly, 50 µl of each sample was loaded into 96-well 
plates and fresh AIR-100-MM media was loaded as a blank.  Next, 50 µl of substrate 
solution was added to each well and the plates were incubated for 30 minutes at room 
temperature in the dark to avoid photobleaching.  At the conclusion of the incubation 
period, 50 µl of stop solution was added to each well.  Absorbance values for the samples 
were then analyzed within 30 minutes of adding the stop solution at the specified 
wavelength of 490 nm using a SPECTRAmax 190 Spectrophotometer with SoftMax® 
Pro software (Molecular Dynamics Corporation, Sunnyvale, CA).  The background 
values were subtracted from each sample and the LDH concentrations were calculated by 
interpolation of a standard calibration curve. 
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Evaluation of Inflammatory Response 
The concentration of interleukin 8 (IL-8) in culture medium was measured 
according to the instructions provided by the manufacturer using a Quantikine enzyme-
linked immunoassay (ELISA) kit from R & D Systems (Ann Arbor, MI).  The kit 
included a microplate coated with a monoclonal antibody specific for IL-8.  One hundred 
microliters of assay diluent followed by 50 µl of sample medium was added to each well 
in the provided plate, then incubated for 2 hours at room temperature.  After washing 
each well, 100 µl of anti-IL8 conjugate was added to each well and the plate incubated 
for 1 hour at room temperature.  The wells were washed to remove unbound conjugate 
solution and 200 µl of substrate solution was added to each well.  The plate was then 
incubated in the dark for 20 minutes.  Finally, 50 µl of stop solution was added to each 
well and absorbance values were measured within 30 minutes at 450 nm (with a 
wavelength correction of 540 nm) using a SPECTRAmax 190 Spectrophotometer with 
SoftMax® Pro software.  The concentration of IL-8 was calculated by interpolation of a 
standard calibration curve. 
Evaluation of Transfection Efficiency 
 Seventy-two hours after the application of naked DNA or PEI/DNA complexes, 
the tissues were washed by gently immersing the collagen support in phosphate buffered 
saline solution (PBS; MatTek Corp.).  Next, 300 µl of 1X Receptor Lysis Buffer was 
added to the apical tissue surface.  The lysates were stored at -80°C until further analysis 
was undertaken.  The lysates were thawed at room temperature then centrifuged for 15 
minutes at 4°C and 2000 rpm using a Thermo IEC, Savant Refrigerated Microcentrifuge 
model SFR13K (Needham Heights, MA).  Luciferase activity was assessed using 50 µl 
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supernatant with 100 µl Luciferase Assay Reagent (Promega Corp., Madison, WI) using a 
Los Alamos Diagnostics model 535 luminometer (Turner Designs, Inc., Mountain View, 
CA).  Total protein was assessed using a Bio-Rad protein assay kit (Hercules, CA) 
according to the manufacturer’s protocol.  The absorbance was measured at 595 nm using 
a THERMOmax microplate reader (Molecular Devices, Sunnyvale, CA). 
DNA Quantification and Analysis 
Control and atomized DNA samples (300 ng) were loaded onto 0.5% agarose gels 
containing 0.5 mg/ml ethidium bromide and run for 4 hours at 70 V in 1X TAE buffer.  
Gels containing plasmid DNA were scanned and analyzed for supercoiled, linear, open 
circle, and fragmented DNA structures using a Fluor-S MultiImager with Quality One® 
software (Bio-Rad Laboratories, Hercules, CA).  The intensity of the bands associated 
with each structure corresponded to the number of DNA molecules, however the intensity 
at which ethidium bromide stains has been shown to be dependent upon DNA topology 
[70].  Therefore, a correction factor of 1.4 was applied to the supercoiled DNA values in 
order to account for the reduced amount of ethidium bromide that binds to this form of 
DNA [70].  Percentages of each DNA structure were then calculated by dividing the 
intensity of each stained band by the total staining intensity (sum of supercoiled, linear, 
open circle, and fragmented DNA).  To dissociate DNA from PEI, polyaspartic acid (25 
mg/ml) was incubated with PEI/DNA complexes for 1 hour at 37°C, and the separated 
DNA was analyzed using agarose gel electrophoresis as described above.   
Statistical Analysis 
Experimentally determined values for supercoiled, linear, open circle, and 
fragmented DNA were compared within a range of applied voltages using a one-way 
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ANOVA.  Additionally, comparisons between application methods as well as applied 
voltages at specific time points were assessed using an ANOVA in conjunction with 
Tukey’s and Fisher’s multiple comparison tests.  Samples having p values less than 0.05 




Prior to investigations with cells, the effect of varying applied voltages on 
supercoiled, open circle, and fragmented structures for both naked and PEI/DNA 
complexes (ratio 1:10) was examined (Figure 2.2A and 2.2B).  The lower applied 
voltages, 0 kV and -3 kV, display dripping profiles while the higher applied voltages, -6 
kV and -7kV, present stable cone-jet and whipping cone profiles, respectively.  A slight 
decrease in supercoiled DNA resulted in a small increase in both the open circle and 
fragmented forms at the two highest applied voltages (Figure 2.2A).  However, the total 
amount of fragmented DNA remained below 10% for both of these conditions.  In 
contrast, supercoiled, open circle, and fragmented DNA structures remained constant for 
all applied voltages when DNA was complexed with PEI (Figure 2.2B).  These results are 
similar to our previous findings [71].     
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Figure 2.2 – Percent of supercoiled (triangle, solid line), open circle (circle, dashed line), 
and fragmented (square, dotted line) structure for naked plasmid DNA (A) or PEI/DNA 
complexes (B) at varying applied voltages.  The amount of supercoiled, open circle, and 
fragmented DNA was assessed with agarose gel electrophoresis.  Each bar represents the 





ALI cultured bronchial/tracheal epithelial cells were utilized to assess the effects 
of delivering naked plasmid and complexed DNA by electrosprays on respiratory 
epithelial cells.  To evaluate toxicity and inflammatory response, we monitored the 
release of the cytoplasmic enzyme LDH and the cytokine IL-8 in the culture medium.  
The extracellular appearances of LDH and IL-8 are commonly used to detect cell 
damage/death and inflammatory response, respectively, in pulmonary gene delivery 
studies [72-78].  Cellular transfection rates were also monitored by measuring the 
expression of luciferase enzyme, which is encoded by the plasmid DNA. 
Our toxicity results indicate that samples exposed to the applied electrical field 
exhibit a slightly increased level of LDH release (Figure 2.3A) when normalized with the 
untreated tissues (a value of 1 indicates levels equivalent to untreated cells).  However, 
this effect is short-lived and the extracellar release of LDH drops back to the control level 
after 8 hours.  It appears that no permanent damage to the cells is caused by the exposure 
of the electric field.  The electrospray’s applied electrical field and exposure time were 14 
and 80 times higher than that of traditional electroporation methods, indicating that cells 
are not affected by these relatively high electric fields [79].  In addition, there is little 
effect on the tissues when applying the Tris-HCl buffer on top of the cells, either by 
pipetting or by processing through the electrospray system at -6 kV (Figure 2.3A).  
Although a slight increase is seen for the sprayed buffer, the difference is not statistically 
significant.  The positive control for this experiment was completed by lysing the tissue 
to determine the total amount of LDH available for release from the cell.   
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The inflammation results for IL-8 are seen in Figure 2.3B.  The difference 
between the control and the buffer (both sprayed and pipetted) for the cytokine release is 
statistically different for early time points but becomes statistically the same once 12 
hours have elapsed (Tukey comparison test).  It is not surprising that the application of a 
fluid to lung cells should elicit a mild cellular response.  The positive control for IL-8 
consisted of the application of one hundred microliters of 0.1 mg/ml LPS.  When 
compared to the positive control that elicited a 3-fold greater response, the effect of 





Figure 2.3 – Induction of LDH and IL-8 in human tracheal/bronchial epithelial cells after 
exposure to the control conditions.  (A) Normalized (divided by LDH levels in untreated 
cells) release of LDH for three control conditions: tissues exposed to a maximum electrical 
field of 7 kV (diamond), tissues with buffer pipetted on top of the cells (square), 
indirectly sprayed buffer applied to tissues after spraying (triangle), tissues subjected to 
sprayed buffer at 6 kV (circle), and, the positive control, lysing of the cells (dash).  (B) 
Release of IL-8 in untreated tissues (diamond), tissues with buffer pipetted on top of the 
cells (square), indirectly sprayed buffer applied to tissues after spraying (triangle), tissues 
subjected to sprayed buffer at 6 kV (circle), and, the positive control, 0.1 mg/ml LPS was 
applied (dash).  From these graphs, it is easy to see that each condition does not deviate 
significantly from the untreated tissues, especially when compared to the positive 
controls.  Each error bar represents a 95% confidence interval of released LDH or IL-8 in 
triplicate tissue samples. 
 
Figure 2.4 depicts the cellular response of the lung cells after the application of 
plasmid DNA.  The results in Figure 2.4A show little change in LDH release with the 
different methods of DNA application.  Similar results are seen for the IL-8 release, with 
the majority of all samples having statistically similar mean values.  The LPS positive 
control is the only sample with a statistically different mean value.  Comparable results 
were seen at other voltages (-3 kV and -7 kV), suggesting that cellular toxicity and 
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inflammation are not affected by droplet charge density and size (data not shown).  
Finally, we did not detect luciferase activity for any condition, indicating that naked 






Figure 2.4 Induction of LDH and IL-8 in human tracheal/bronchial epithelial cells after 
administration of naked plasmid DNA.  Release of the enzymes were monitored in 
untreated tissues (diamond), DNA not processed through the system but pipetted 
directly onto the tissues (square), indirect application of aerosolized DNA (triangle), and 
direct spray application of DNA (star for 0 kV and circle for 6 kV).  (A) Normalized 
results for LDH release.  (B) Results for the IL-8 release.  The positive control used for 
the both graphs was the same as in Figure 2.3 but left off for clarity.  Each error bar 
represents a 95% confidence interval of released LDH or IL-8 in triplicate tissue samples. 
 
Previous studies attempting to deliver DNA to the lungs observed enhanced gene 
expression when DNA was condensed through complexation with other polymers and 
lipids [25, 29, 32, 34, 80-83].  Figure 2.5 displays cumulative LDH and IL-8 release after 
administration of PEI/DNA complexes.  A significantly different response is evident 
when complexes are applied at different PEI/DNA ratios, regardless of whether the 
complex was sprayed via EHDA.  It appears that a 10:1 ratio of PEI to DNA is toxic to 
the cells while a ratio of 6:1 is not (this includes the PEI alone; the amount of PEI used is 
the same as in the 6:1 ratio).  Despite complexing the DNA with PEI, we did not detect 
luciferase expression for any of the formulations tested.  Since the main objectives of this 
entire study were to evaluate toxicity and inflammatory response, we did not conduct 





Figure 2.5 – Induction of LDH and IL-8 in human tracheal/bronchial epithelial cells after 
EHDA spray administration of various PEI/DNA complexes at an applied voltage of 6 




tissues subjected to sprayed DNA (circle), tissues exposed to PEI/DNA complexes not 
processed through the system (square t), tissues exposed to EHDA PEI/DNA complexes 
with direct spray application with a ratio of 1:10 (star) and 1:6 (square), and tissue 
subjected to sprayed PEI alone (triangle).  (A) Normalized results for LDH release.  The 
positive control was left off for clarity.  (B) Results for the IL-8 release.  The positive 
control used for the IL-8 experiments was 0.1 mg/ml LPS (dash).  Each error bar 
represents a 95% confidence interval of released LDH or IL-8 in triplicate tissue samples. 
 
In the interest of further exploring the effects of agents commonly used to deliver 
DNA, other polymers and lipids were used to complex DNA.  Additionally, the toxic 
effects of the PEI complexes were investigated more thoroughly.  In Figure 2.6, the 
results for toxic and immune responses to various DNA complexes are shown.  It appears 
that all of the complexes have a negligible effect on the tissues with the exception of the 
modified PEI when applied alone.  In contrast to application of the regular linear PEI 
(Figure 2.5B), the modified PEI elicited a small immune response when administered 
alone (slight increase in IL-8 release, Figure 2.6B).  The reason for this is unclear, but it 





Figure 2.6 – Induction of LDH and IL-8 in human tracheal/bronchial epithelial cells after 
EHDA spray administration of various DNA complexes at an applied voltage of 6 kV.  
Release of the cytokines was monitored in untreated tissues (diamond), tissues exposed 
to naked plasmid DNA processed through the system (circle), tissues exposed to EHDA 




complexes sprayed using EHDA directly onto the tissues (triangle), tissues directly 
sprayed with modified PEI/DNA complexes (star), and tissue subjected to sprayed 
modified PEI alone (square t).  (A) Normalized results for LDH release.  The positive 
control for the LDH was left off this graph for clarity (values can be seen in Figure 2.3).  
(B) Results for the IL-8 release.  The positive control was left off of the graph for clarity.  
Each error bar represents a 95% confidence interval of released LDH or IL-8 in triplicate 
tissue samples.  The * represents a statistically significant difference between the 
modified PEI and the other treatments. 
 
2.5 Discussion 
By applying significant voltages to a fluid stream, EHDA sprays can produce 
droplets when the electrical forces are great enough overcome the fluid’s surface tension.  
This aerosolization method has a wide range of uses from chemical analysis via mass 
spectrometry to the encapsulation of immiscible liquids on a micro/nano-scale to 
delivering agricultural pesticides [84, 85].  Yet, the use of EHDA sprays for pulmonary 
drug delivery remains in its infancy.  When not complexed to a cationic agent, native 
DNA is degraded upon atomization by current aerosolization devices such as jet and 
ultrasonic nebulizers [23, 24, 71, 86, 87].  In contrast, we have previously shown EHDA 
sprays to be a gentle method by which naked plasmid DNA can easily be aerosolized 
without substantial losses in native DNA structure (Figure 2.2A) [71].  Furthermore, 
complexing DNA with PEI resulted in complete maintenance of DNA conformation 
(Figure 2.2B).  Considering the ability of these methods to maintain DNA integrity, the 
goal was to test the effect of EHDA sprays on respiratory epithelial cells. 
The development of epithelial cell culture models that resemble in vivo conditions 
has shown great promise [88-90].  Advantages of using these cell culture models include: 
small amounts of therapeutics are required, they are easier and more economical than in 
vivo studies, reducing the need for animal testing, and environmental conditions such as 
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pH and temperature can easily be controlled [62]. A highly differentiated, three-
dimensional in vitro model that forms tight cellular monolayers with mixed cellular 
phenotypes (e.g., ciliated and non-ciliated cells) capable of secreting mucus or surfactant 
is highly desirable since it more closely mimics in vivo airway tissue.  To this end, 
protocols for the isolation of primary respiratory epithelial cells originating from both 
humans and animals have been developed [91-94].  However, a limited number of 
primary cells can be freshly isolated from their donor and, depending upon the culture 
technique, morphological and functional changes can occur [95].  Cancer cell lines have 
also been examined for their suitability to serve as cell culture models [96-100].  
Unfortunately, these cancer cell lines can exhibit several abnormal characteristics in 
addition to their immortality.  In this investigation, we utilized commercially available 
ALI cultured bronchial/tracheal epithelial cells to assess the toxicity, cytokine response, 
and delivery of naked plasmid and complexed DNA by electrosprays. 
 Our results showed that the toxicity and inflammatory responses after 
aerosolization of naked DNA and the DNA complexes were similar over the investigated 
time span.  Furthermore, the results indicate that cells subjected to the applied electrical 
field do not exhibit a prolonged release of LDH (Figure 2.3A), and cells are able to 
recover quickly from the initial exposure.  Regardless of the condition, the release of 
extracellular IL-8 is consistent (except for the positive LPS control).  An unexpected 
finding was that the results for the PEI complexes show a PEI/DNA ratio of 10:1 was 
extremely toxic and immunogenic, whereas the 6:1 ratio was statistically similar to the 
control.  Other studies have also seen the same rise in toxicity with an increase in PEI 
ratio in vivo [101].   Consistent with the studies by Russ et al. (2008), the modified PEI 
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exhibits little toxicity when complexed with DNA [69].  However, we find that the 
modified PEI is toxic when delivered alone, similar to that observed for free linear PEI 
[69, 102].  
 The primary barrier for efficient delivery of therapeutics to the lungs is the 
epithelial lining.  The apical surface of the epithelium displays a number of features that 
present barriers to the uptake of foreign material.  The cell monolayers are comprised of 
polarized cells that contain tight junctions that prevent the passage of everything but very 
small polar molecules.  Also, the endocytic capacity of these cells is limited.  In addition, 
goblet cells within the epithelium secrete mucus that inhibits diffusion of foreign 
particles, thereby reducing access to the plasma membrane.  In the bronchial regions of 
the lung, the apical surface is coated with cilia that beat continually in order to move 
foreign materials away from the lung.  In the deeper regions of the respiratory tract, 
alveolar macrophages remove the foreign material, typically via phagocytosis [17, 62].  
While delivery to the cultured ALI cell system is clearly different from delivery to the 
lung (e.g., shorter distance between electrospray and apical cell surface), the cells mimic 
the lungs by being fully differentiated and able to produce mucus.  Consistent with our 
inability to detect expression of the luciferase reporter gene, numerous studies have 
demonstrated the difficulties associated with transfecting differentiated epithelial cells 
found in the lungs [103-108].  In addition to the barriers presented by secreted mucus and 
the presence of tight junctions preventing the passage of foreign materials to the plasma 
membrane, differentiated cells divide relatively slowly which reduces access to the 
nucleus [109].  
33 
 Considering the minimal effect on toxicity and inflammatory response observed 
despite a very large range in droplet charge (calculated droplet charge ranged from 0 
C/m2 at 0 kV up to 2.2 x 10-5 C/m2 at -7 kV), the results demonstrate that exposure of the 
EpiAirway™ cells to electric fields and charged droplets during electrospray 
administration do not have detectable adverse effects.  Although our experimental 
conditions did not result in successful transfection, the maintenance of DNA integrity 
combined with the lack of toxicity and minimal inflammation suggest that electrosprays 
are a potentially safe and effective method for the pulmonary delivery of genetic 
therapeutics.  Additional experiments would need to be conducted in order to optimize 
transfection efficiency and assess the applicability of this approach in vivo.  In addition, 
the ability of EHDA to accurately vary droplet size, and thereby target different regions 
of the lung, offers significant advantages over conventional nebulizers. 
2.6 Conclusion 
Our investigation shows electrosprays to be a gentle method by which plasmid 
DNA can be aerosolized without a significant loss in native DNA structure.  This 
investigation explored the effects of aerosolization of naked and complexed plasmid via 
an electrospray on EpiAirway™ cells that had been cultured at an air-liquid interface.  
LDH release remained low for both the naked and complexed formulations indicating 
minimal cell toxicity (except for the 10:1 PEI/DNA complex).  In addition, cytokine 
levels appeared nominal and comparable for all conditions, independent of electrospray 
application.  The mild toxicity observed when the tissues were placed in the applied 
electric field was temporary, and the tissues returned to normal within a few hours after 
application.  Our experiments were designed to assess the toxicity associated with EHDA 
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sprays; however future studies would be needed to optimize this approach for 
maximizing transfection.  While future in vivo experiments are required, our results show 
that electrosprays present a promising method for administering DNA-based therapeutics 
















































Since its emergence in the early 1980s, molecular biotechnology, especially the 
promise of protein therapies, has not reached its full potential.  This is due, in part, to the 
cost of the therapies but also to the unpredictable nature of these macromolecules during 
processing and delivery.  There are currently 85 protein-based therapeutics marketed for 
pulmonary delivery, with at least 350 more in clinical trials [110].  In addition to those 
already targeted for aerosol delivery, a majority of proteins are spray dried to increase 
shelf life.  The ability of a protein to sustain activity or native structure after 
aerosolization has largely been a mystery for process and formulation designers. 
In 1997, Maa et al. found a correlation that associated protein stability with 
surface area to volume ratios [9].  They noted a linear relationship between droplet 
diameter and protein aggregation.  Furthermore, they believed that over time more 
proteins would be drawn to the interface causing greater protein denaturation and 
aggregation.  The implication of their statement is that protein degradation by 
aerosolization is a time dependant process.  However, studies in our lab showed no 
change in degradation of a protein within stationary droplets; suggesting that time is not 
an influencing parameter but instead drop size might be a factor. 
Significant literature exists on the aerosolization or atomization of proteins using 
EHDA.  However, a large portion of published research has failed to observe protein 
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functionality directly after spraying [111-116].  Of those that did monitor protein activity, 
findings are inconsistent.  For example, Gomez et al. examined insulin and found no 
change in activity between the sprayed versus non-sprayed samples [10].  A few studies 
examined the effects of spraying bovine serum albumin (BSA).  Pareta et al. investigated 
the secondary structure of BSA using circular dichroism and reported a slight but 
insignificant change in structure [12]. The paper pointed out that increased protein 
concentrations correlated to less structural degradation of BSA.  Similarly, Xie et al. 
electrosprayed BSA in tandem with a polymer to study encapsulation [117, 118].  They 
found that BSA retained more than 80% of its original activity.  For lactate 
dehydrogenase and pyruvate kinase, parameters such as voltage and co-solvent 
concentration had to be manipulated in order to maximize protein stability [119].  
Gowadia and Dunn-Rankin [120] implemented an assay to determine the activity of a 
lipase enzyme after spraying.  They found that the activity of the protein dropped from 
90% of the non-sprayed activity to 43% when decreasing the flow rate from 29 cc/hr to 9 
cc/hr.  This drop in activity is consistent with Maa’s hypothesis because Ganan-Calvo 
[121] has definitively shown that lowering the flow rate in the EHDA process decreases 
the drop size.  Maa would therefore predict a large reduction in protein activity with the 
subsequent increase in the surface area to volume ratio associated with this decrease in 
droplet size.   
More recently, Randolph et al. predicted an additional relationship beyond surface 
area to volume ratio.  They recommend for a protein to remain stable its change in 
surface tension divided by change in surface area must be greater than zero, else the 
protein unfolds [13]. However, this theory, as well as Maa’s, fails to capture the dramatic 
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differences in fragility between different proteins or even protein batches.  As such, a 
universal theory must observe energy input to the system to create the aerosol relative to 
the activation energy required by the protein to jump to a new energy well within the 
potential landscape and subsequently unfold. 
Undoubtedly, the pharmaceutical protein industry would greatly benefit from a 
simple correlation between easily measurable formulation quantities and the smallest 
active droplet size for sustained protein stability.  The work outlined in this chapter 
exploits thermodynamic relations utilizing several simplifying assumptions to develop a 
universal correlation between surface tension, melt enthalpy in solution, and droplet size 
for predicting protein stability during aerosolization.  We present a series of experimental 
data that validates this correlation and defines a transition region. 
 
3.2 Thermodynamic Theory and Derivation 
Proteins remain in their native, folded form until sufficient energy is added to the 
system, which subsequently drives the proteins into a new energy potential well enabling 
them to unfold.  The amount of energy required to unfold a protein can be measured 
using a differential scanning calorimeter (DSC).  The DSC applies a constant heating rate 
to both a blank cell (consisting of the buffer solution) and sample cell.  As the protein 
unfolds, the energy applied to the sample cell is used for unfolding and not to heat the 
cell.  It is at this juncture that a temperature difference between the two cells occurs and 
requires additional heating power to bring the sample cell to the temperature of the blank.  
The heating power is directly related to the heat capacity (cp) of the sample.  The 
temperature at which the protein unfolds is known as the melting temperature (Tm).  As 
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the scan progresses, the heat capacity and temperature of the sample are recorded and can 
be manipulated to give the melting enthalpy (dHm) of the sample. 
! 
dHm =c p *dT     (3.1) 
In order to use this relation, the protein must be reversible, meaning that the protein must 
refold to its original form upon cooling.  This assumption is required to relate heating 
power to heat capacity. 
 The aerosolization of a protein solution requires energy to break the initial liquid 
bulk or column into individual droplets.  This energy includes disrupting the surface 
tension of the liquid and increasing the surface area.  The total enthalpy (HT) of the 
closed aerosolization process or system can be explained by breaking the enthalpy of the 
system into three parts: the air (HA), the surface of the drop (Hσ), and the drop bulk (HB). 
! 
dHT = dHA + dH" + dHB
dHA = TdS+VdP+ #µdni
dHB = TdS+VdP+ #µdni
dH" = TdS+"dAS + #µdni
    (3.2) 
Where the enthalpy depends on temperature (T), entropy (S), volume (V), pressure (P), 
surface tension (σ), surface area (As), number of molecules (ni), and chemical potential 
(µ).  Assumptions can be made to simplify these equations.  In the part of the system 
comprised only of air, no heat is transferred and pressure remains constant.  If 
evaporation is negligible from the droplet, the number of air molecules and composition 
of the air does not change, thus having no change in enthalpy for the air. 
! 
dHA = 0     (3.3) 
For the bulk solution in the drop, it can be assumed that no energy in the form of heat is 
transferred in the system, thus the TdS term is assumed negligible.  Note this would not 
39 
necessarily be true in spray drying when evaporation is important, but it is a correct 
assumption for inhalation applications. 
! 
dHB = VdP+ ("µdni )B     (3.4) 
At the interface of the drop, there is no heat transfer (evaporation is insignificant on this 
time scale).  Again, the TdS term is neglected. 
! 
dH" = "dAS + (#µdni )"     (3.5) 
Combing the three simplified equations, the total enthalpy of the system becomes: 
! 
dHT = "dAS +VdP+ (#µdni )T    (3.6) 
 
Relatively low pressures are used to generate the aerosol for this study, as is true for most 
inhalation and spray dryers, the greatest pressure extending to about 100 psi.  Research 
concerning protein denaturation due to pressure is seen at high pressures, greater than 
2,000 kbar (see Table 3.1) [122-124].  For this reason, enthalpy changes due to the small 
pressure changes in our system are also assumed to be negligible.  This leaves a final 
equation that is dependent on surface tension, change in surface area, and change in the 
number of proteins at the surface and bulk.  It is important to realize that the chemical 
potential of the proteins at the surface is different than the bulk not only because they 
might be denatured but also because they will partially unfold to expose hydrophobic 
regions to the gas phase. 
TiST
dndAdH )( µ! "+=    (3.7) 
Table 3.1 - Common proteins and the pressures at which they denature. 
Protein Pressure to Denature at 20oC 
(kbar) 
SNase 2,000 
α – Chymotrypsin 4,000 
RNase A 6,000 
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Ubiquitin 5,500 
rs GFP 9,000 
 
It is assuring that this new relationship is consistent with Randolph’s realization that there 
is a direct relationship between surface tension and drop size, which affects the stability 
of a protein [13, 125, 126].  Moreover, this new relationship acknowledges the difference 
in melt enthalpy from one protein to another.  However, it is important to recognize that 
there is an inherent dependence of the chemical potential term on the surface area term in 
Equation 3.7.  Decreasing the droplet diameter increases the surface area to volume ratio 
thus impacting the chemical potential term simply though changing the number of protein 
molecules in the bulk compared to the surface.  As chemical potentials are difficult to 
accurately and simply measure, we will assume a proportional relationship and condense 
the expression into a single function with C as the proportionality constant.  Experimental 












     (3.8) 
Coupling the DSC system and Equation 3.1 with the aerosolization system and 
Equation 3.8, we propose that if the total energy of the drop is greater than that of the 
melting enthalpy, the protein will denature. 
! 
dHM < C *"dAS      (3.9) 
 
3.3 Materials 
All of the chemical and biological materials were purchased from Sigma-Aldrich 
(St. Louis, MO) and include: choline oxidase (Alcalignes), potassium chloride [KCl], 
ethylenediaminetetraacetic acid [EDTA], choline chloride, phenol, 4-aminoantipyrine, 
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peroxidase (horseradish type II), Trizma® base [Tris], Trizma® hydrochloride [Tris 
HCl], potassium phosphate (mono- and di- basic) [KPO4], o-nitrophenyl b-d-
galactopyranoside, magnesium chloride [MgCl], 2-mercaptoethanol, β-galactosidase (E. 
coli), methanol, n-(2-hydroxyethyl) piperazine-n (3-propanesulfonic acid) [EPPS], n-
benzoyl-l-tyrosine ethylester [BTEE], methanol [MeOH], calcium chloride, α-
chymotrypsin (bovine pancreas type II), citrate synthase (porcine heart), oxaloacetic acid, 
acetyl coenzyme A, and 5,5’-Dithiobis (2-nitrobenzoic acid) [DTNB].  All solutions were 
prepared with deionized water.  For each enzyme, the buffer solution was made using a 
variety of different pH values (Table 3.2).  The purpose of varying the pH was to create 
protein solutions possessing different melt enthalpies and surface tensions.   
Table 3.2 – Buffer, concentration, and pH for each protein. 
Protein Concentration of Buffer 
Used 
pH Used 
100 mM Potassium Phosphate 6.7, 7.2, 7.7 
Choline Oxidase 10 mM Tris HCl, 2mM EDTA, 
134 mM KCl 
7, 8, 8.5 
β-Galactosidase 100 mM Potassium Phosphate 7.2 
10 mM EPPS 7.2, 7.6, 7.8, 8, 8.4 α-Chymotrypsin 
80 mM Tris HCl 7.5, 8, 8.5 




The device used to create the drops for this investigation was a piezoelectric 
droplet generator (Figure 3.1).  The fluid was pumped through a syringe pump (Model 
260D, ISCO Inc.) at a constant velocity of 1 ml/min and the fluid was passed through a 
vibration orifice.  A piezoelectric ceramic, similar setup to Berglund et al. [127], vibrates  
creating perturbations in column momentum leading to surface waves that are amplified 
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by aerodynamic interaction.  This in turn pinches off uniformly sized drops from the 
liquid jet.  The size of the drop is controlled by both the frequency of the piezoelectric 
and the diameter of the vibrating orifice, both of which are easily manipulated by either 
changing the frequency or by replacing the orifice disk.  For these experiments, the 
frequency was kept at approximately 20 kHz because each piezoelectric ceramic exhibits 
a natural frequency leading to an optimal performance octave frequency.  Therefore to 
manipulate the final term in our relationship we employed three orifice disks with 
diameters of 25, 50, and 75 microns.  The drop generator had a tendency to become 
obstructed, so a 7 micron stainless steel Swaglok® inline filter was placed between the 
pumps and the piezoelectric. 
 
Figure 3.1 - Diagram of the drop generator, which uses a piezoelectric to create 
monodisperse drops.  Image was modified from Berglund et al. 
 
Particle Sizing by Imagery 
 The drops were imaged using a CCD camera (Model DT100) and software 
(CameraLink v1.02h) by DuncanTech with a field of view pixel size of 1024 x 1024.  As 
drops were being generated, a strobe light was flashed behind the drops and still images 
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were taken.  In addition, pictures of a sub-millimeter ruler were taken.  The drop images 
were sized by pixel using an onscreen pixel ruler (Pixel Ruler v3.1, Mioplanet 
Technologies Inc.) and converted to millimeters using the ruler images.   
Activity Assays 
Enzymatic assays were used to determine the structural stability and activity of 
each of the proteins before and after aerosolization.  The assays were colorimetric in 
nature and were analyzed using a UV spectrophotometer (Model USB 2000+, Ocean 
Optics).  By observing the rate of product formation, the assay was able to show the 
activity of the enzyme and thus the structural stability.  The rate of activity of the 





*100   (3.10) 
The activity for each condition was monitored at room temperature (approximately 25 
oC) and measured in triplicate. 
The assay for β-galactosidase was found in [128] and briefly described below.  To 
monitor the activity of β-galactosidase, the following solutions were mixed into a 
cuvette: 
  0.175 ml of 100 mM KPO4 
  0.033 ml of 30mM MgCl 
  0.033 ml of 3.36 M 2-mercaptoethanol 
After the β-galactosidase had been processed, 0.033 ml of the 4 units/ml enzyme solution 
were added to the cuvette.  At time zero 0.033 ml of 68 mM o-nitrophenyl b-d-
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galactopyranoside was added and the absorbance of the reaction was recorded at 410 nm 
for 5 minutes. 
The reaction for choline oxidase was described in detail by Sigma-Aldrich [129, 
130].  The first step in monitoring the activity of the protein was to create the following 
reaction cocktail. 
   24.25 ml of 2.1% w/v choline chloride 
     0.25 ml of 1% w/v 4-aminoantipyrine 
   0.5 ml of phenol 
   ~ 1 mg of Peroxidase 
The final solution was light sensitive and needed to be stored appropriately, i.e., wrapped 
in aluminum foil until used.  When ready, 0.988 ml of the cocktail was added into a 
cuvette and placed in the spectrophotometer with the absorbance reading set to 500 nm.  
After the choline oxidase had been aerosolized, 0.025 ml of the 0.3 unit/ml solution was 
collected and placed in the cuvette.  The absorbance was recorded at 500 nm for 5 
minutes with readings collected at least every 10 seconds. 
 The UV spectrophotomic reaction for α-chymotrypsin was first discovered by 
Wirnt [131] but later improved by Rafiq and Bailey [132].  The assay for α-chymotrypsin 
required the following solutions: 
   1.07 mM BTEE in 4.2% v/v MeOH 
   0.08 M Tris HCl with 0.1M CaCl 
After the solutions were prepared, 0.467 ml of the BTEE solution was placed in a cuvette 
with 0.5 ml of the Tris HCl solution.  The cuvette was placed in the UV 
spectrophotometer and the absorbance was set to 256 nm.  Sprayed chymotrypsin was 
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collected and 0.03 ml of the 1 mg/ml enzyme was added to the cuvette.  The absorbance 
was recorded at 256 nm for 5 minutes, with readings collected at least every 10 seconds.   
 The assay used in the UV spectrophotometer for citrate synthase contained:   
  1 mM DTNB in 1M Tris HCl (pH 8) 
  10 mM oxaloacetic acid in 0.1 M Tris HCl 
  10 mM acetyl coenzyme A 
The assay was first discovered by Srere in 1966 [133, 134] and requires 0.05 ml of 0.4 
units/ml sprayed citrate synthase, 0.1 ml of DTNB, 0.03 ml of acetyl coenzyme A, 0.77 
ml of deionized water, and the last solution added at time zero was 0.05 ml of oxaloacetic 
acid.  The peak absorbance was at a wavelength of 412 nm and absorbance readings were 
collected for 5 minutes at 10 seconds intervals. 
 
Calorimetry 
The calorimetry measurements were determined using a differential scanning 
calorimeter (model VP DSC, MicroCal) operating with Origin 7.0 software (MicroCal 
Piscataway, NJ). The volume for each cell was 0.51 ml.  The blank cell was always filled 
with the same buffer as that of the protein under examination to provide a blank signature 
for reference.  Each run was typically scanned from 10oC to 100oC at a rate of 90oC/hour 
and at a constant pressure of about 36 psi.  The reference buffer scan was subtracted from 
each enzyme sample to create a stable baseline.  The activity assays were more sensitive 
to concentration than the calorimeter; therefore greater concentrations of proteins were 
used in the calorimetry experiments (Table 3.3). 
Table 3.3 - Concentration of proteins used for DSC experiments. 
Protein Concentration Used (mM) 
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β-Galactosidase 0.000564 
Choline Oxidase 0.000556 
α-Chymotrypsin 0.04 
Citrate Synthase 0.0014 
 
Surface Tension 
Surface tension was measured with a tensiometer (model Sigma 701, KSV 
Instruments Monroe, CT) using the ring method (DuNouy).  As the ring lifts out of a 
liquid, there is a force pulling on the ring from the liquid.  A maximum force is exerted 
on the ring just before the liquid breaks, which is a measured by the tensiometer, and is 
equal to the surface tension of the liquid.  The protein solutions used for this 
measurement were identical to those processed through the drop generator.  
Measurements were taken in triplicate for each condition and then averaged. 
Surface Area 
The change in surface area was calculated between the unprocessed protein 
solution in the drop generator and the droplets formed.  For the total enthalpy calculation 
proposed, it is important to maintain the same volume or mass on each side of the 
equation.  Thus the volume for the aerosolization calculation (Equation 3.8) was the same 
as what used in the DSC (0.51 ml) calculation in Equation 3.1.  The mass must be 
maintained so that the two total enthalpies can be set equal.  This is equivalent to 
rewriting the equations in the enthalpy per mass form.  The surface area of the drop 
generator that corresponded to the volume used in the DSC was 2.8 cm2.  
Data Analysis 
At a minimum, each experiment was conducted in triplicate.  All error bars 




In order to fully test the theory presented in Equation 3.8, all three of the parameters 
were tested.  Each parameter (surface tension, drop size, and melt enthalpy) was 
manipulated in different ways by altering the buffer, pH, protein, and orifice size.  The 
values obtained for all experiments are shown in Table 3.4.   
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Table 3.4 – Experimental data obtained for all techniques.  Errors reported are equal to 

















0.005 7.2 96 ± 4 60% ± 9 0.29 ± 0.04 70 ± 0.4 
0.083 7.7 100 ± 20 49% ± 8 0.18 ± 0.03 59.3 ± 1.1 
0.083 7.2 87 ± 19 77% ± 8 0.27 ± 0.03 64.9 ± 0.08 
Choline 
Oxidase 
(Phosphate) 0.083 6.7 103 ± 10 65% ± 16 0.14 ± 0.02 59.3 ± 2.7 
0.083 8.5 120 ± 9 68% ± 11 0.33 ± 0.02 69 ± 1 
129 ± 20 38% ± 16 
0.083 8 
154 ± 16 79% ± 9 




0.083 7 125 ± 19 75% ± 15 0.14 ± 0.04 70 ± 1 
1 8.4 140 ± 20 92% 8.7 ± 0.5 55.3 ± 1.2 
1 7.6 135 ± 19 80% 10.5 ± 0.6 56.7 ± 1.2 
1 7.15 132 ± 22 93% ± 10 10.75 ± 0.6 57.0 ± 1.2 
0.5 8 121 ± 29 63% ± 12 5.4 ± 0.5 61.5 ± 1.2 
Chymotrypsin 
(EPPS) 
0.8 7.8 94 ± 13 95% ± 20 6.9 ± 0.2 59.3 ± 1.9 
Chymotrypsin 
(Tris) 
1 8 140 ± 29 80% ± 10 6.2 ± 0.5 59 ± 1.9 
67 ± 13 2 ± 0.6 




71 ± 15 14.2 ± 3.6 
0.78 ± 0.1 66.9 ± 2.8 
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The three orifice disks created drops about twice the size of the diameter used.  
The 75 micron orifice disk routinely produced drops in the 140 micron range; while the 
50 micron disk created drops around 100 microns.  The 25 micron disk made drops 
around 60 microns.  
 The enzymatic assays were not precise in nature and the majority of them gave an 
error in the range of 10%.  Although the error seems large, a trend in stability is 
consistently seen in the data.  Table 3.4 shows the activity of each protein after 
processing through the drop generator, where the percentage refers to amount of activity 
retained compared to the positive control. 
 Enthalpy data was obtained from the DSC scans.  Each scan contained heat 
capacity versus temperature information.  As the protein unfolded, a peak was seen in the 
heat capacity data.  The melting enthalpy was calculated at the peak by integrating the 
area under the curve.  The enthalpy results are enumerated in Table 3.4. 
 Surface tension measurements were taken directly after adding the protein into the 
solution.  The reported numbers are instantaneous surface tension, also known as 
dynamic surface tension.  This was measured in place of static surface tension; a value 
averaged over a long period.  When the aerosol system creates a drop, it is assumed that 
the concentration of protein is equal throughout the solution.  As the surface is created, 
protein is drawn to the surface to reduce the free energy of the system.  In order to fit 
with our theory, it is therefore important to measure the surface tension as soon as the 
solution is created.  Values for surface tension are reported in Table 3.4. 
All the data presented in Table 3.4 was plotted using the relationship in Equation 
3.8.  If the hypothesis is correct, then all the data should collapse onto a single trend line 
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that has full activity above a transition region and no activity after the transition value.  
Since the theory has no time dependent term, the transition point should be rather sharp 
with large variability of the data along that transition line. 
There is significant variability in protein activity in the fully active region.  We 
know from the experiments with β-Galactosidase that some protein degradation occurs 
due to interaction with the materials in the fluid handling system, most likely with the 
high surface area sintered metal filter.  Thus the 100% activity label on the Figure 3.2 is 
misleading as it is for completely unprocessed protein.  
From the Figure 3.2, a clear and rapid decline in activity occurs as predicted.  This 
is the transition region between the stable and unstable protein form and represents the 
value of the constant C we were trying to obtain (Equation 3.9).  The transition is found 
in a region centered around a value 100.  The broadness of the transition value is not 
surprising since we made a rather large assumption regarding the functionality of the 
chemical potential term.  However, the transition appears fairly uniform and does not 
appear to be protein dependent.  This finding is quite unexpected though very exciting. 
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Figure 3.2 – Relationship between melting enthalpy, surface tension, drop size and a 
protein’s activity after aerosolization.  A transition is seen around 100. 
 
The majority of the points fit the transition line and supports the trend.  There is 
one data point that resides in the stable region but is suspiciously low.  It contained 
chymotrypsin in EPPS buffer at a pH of 8 and a protein concentration of 0.5 mg/ml.  
Every possible weakness was examined to find a potential flaw in the data point, 
including: pH, flow rate, and pressure of the spray system; contamination of the buffer or 
protein; consistency in all data points; and correlation between preparation and run time.  
No inconsistencies in the data were found.  However, given that the other 17 data points 
follow the trend, we feel that another unidentified mechanism must be driving the 
degradation. 
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The value for the constant C in Equation 3.9 appears to be centered about 100.  It 
was known that the value of the proportionality constant would be greater than one since 
the chemical potential term was incorporated into the surface tension term.  The transition 
for all proteins used is fairly uniform; therefore the value of C does not appear to be 
overly protein dependent.   
Applying Maa’s data [9] to the theory described in Equation 3.9 provides further 
validation that this transition value is not protein dependent (Figure 3.3).  In using this 
data, three assumptions were made 1) percent activity equals one minus percent 
aggregation, 2) surface tension does not vary significantly with concentration, and 3) 
melting enthalpy does not vary with concentration.  A protein can denature without 
aggregation and aggregation occurs at a slower rate than loss in activity, leading to a 
lower transition value and a gradual decline rather than a rapid transition line.  
Furthermore, surface tension does decrease with increasing concentration, thus Maa’s 
data will shift slightly to higher values.  Therefore the first sign of aggregation in Maa’s 
data should be identified as the transition criteria consistent with the data in Figure 3.4.  




Figure 3.3 - Graph of protein data from Maa et al [9].  The plot shows that a decrease in 
melting enthalpy of the protein correlated to a decrease in protein activity. 
 
3.6 Conclusions 
The theory presented in this paper will be incredibly useful for the pharmaceutical 
industry.  Formulation and process designers can now take early stage proteins that show 
therapeutic benefits and conduct two simple tests to determine spray-ability.  From those 
tests, the company will know the smallest, therapeutically active drop they can create 
with the solution without denaturing the protein.  Furthermore, we have identified two 
easy parameters on the formulation “worksheet” to increase protein stability at smaller 
droplet sizes: the addition of excipients and modification of buffers.  To increase 
confidence in stability, we recommend that any protein formulation designer stay 











4 Liposome Creation Using EHDA 
 
4.1 Introduction 
Biological macromolecules represent a new class of mechanism-based-therapeutic 
agents.  Successful development of this new class of therapeutic agents is reliant on 
process and delivery issues that are dramatically different than traditional small 
molecules.  One successful strategy utilizes a protective coating to increase efficacy and 
enhanced specificity and targeting.  The range of encapsulation or entrapment techniques 
is enormous, spanning from existing biological systems (i.e., viral vectors) to synthetic 
vectors (i.e., liposomes, polymer micro particles etc.).  Specifically for the delivery of 
DNA, two strategies have risen above the rest.  Delivering naked DNA is difficult in that 
it not only needs to be protected and tends to elicit an immune response when exterior to 
the cell, but the large size of DNA requires condensation in order to facilitate transport to 
and across the cell and nuclear membranes.  The original successful gene therapies used 
viral vectors to achieve these goals.  Adenoviruses were able to successfully transfect 
cells, but induced inflammatory and antibody responses [135-138].  Other virus vectors 
have been used, including adeno-associated virus and lentivirus, but because of their 
small size have limited encapsulation capacity.  Another approach has been to utilize 
non-viral vectors.  These are synthesized vectors using biocompatible polymers or lipids, 
which do not exhibit mutagenesis or elicit inflammatory responses.  One technique is to 
use Polyethylenimine (PEI) or other cationic molecules that easily bind (i.e., complex) to 
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DNA causing a physical condensing of the DNA size into small, hard particles [35-41].  
However, PEI can be toxic depending on the concentration used [45-50].  More 
importantly, the subsequent unbinding of DNA from the cationic molecule is difficult but 
a prerequisite for transfection to occur.  Therefore, it would be worthwhile to create a 
vesicle that is non-immunogenic, non-toxic, and neutrally charged.  The liposome fits this 
requirement.  It is a soft, spherical vesicle consisting of two layers of lipids (a bilayer) 
and can carry no charge if neutral lipids, known as zwitterionic, are used.  Liposomes are 
not new constructs.  There are numerous techniques for their production, all carrying 
unique process and delivery problems. 
Liposome Creation Methods 
Although liposomes are rather simple in their components, they can be difficult to 
create and even more difficult to efficiently encapsulate material.  Many techniques are 
currently used to produce encapsulated liposomes.  However, the major techniques fit 
into four distinct types: dry lipid films or emulsion, micelle-forming detergents, and 
solvent injection.  
Starting with a dry lipid film coating the bottom of a flask, lipids can be hydrated 
with the aqueous drug solution to be encapsulated.  After the addition of the aqueous 
phase, the flask is agitated for several minutes up to many hours.  These film-hydration 
methods typically create multilamellar vesicles with high encapsulation efficiency.  
However, they have great variations in size, size distribution, and lamellarity. 
First introduced in 1978 by Szoka and Papahadjopoulos [139], reverse phase 
evaporation works by suspending small drug-containing aqueous drops in excess organic 
solvent.  A phospholipid monolayer accumulates at the interface and stabilizes the 
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aqueous drops.  The organic solvent is slowly evaporated and the micelles transform into 
a viscous gel-like state and then eventually to liposomes.  Encapsulation efficiency of this 
system is dependant on the lipids and organic solvents used as well as their ratio.  
Typically the encapsulation efficiency ranges around 30 - 45 % for proteins [140].  The 
major drawback is the exposure of the material to organic solvents, which can lead to 
denaturation of proteins. 
Detergent depletion works by mixing a detergent in with the lipids in the dry 
state.  Once an aqueous solution is added, micelles form.  The solution is put through a 
dialysis that slowly removes the detergent over time.  The detergent helps create vesicles 
that are uniform and small in size.  However, this method is very time consuming and 
costly due to the detergent [141].  
Solvent injection methods typically inject an alcohol solution, containing lipids, 
very slowly into an aqueous phase.  This leads to the formation of unilamellar vesicles.  
The alcohol must then be removed via dialysis against water.  These liposomes have a 
small size distribution and very low encapsulation efficiencies (25-27%) [142].   
Double emulsion techniques are a two-step emulsion process that begins similarly 
to the reverse phase evaporation.  Aqueous drops are stabilized by lipids in an organic 
solution.  The mixture is then added into a new aqueous phase creating a double 
encapsulation.  The issues with this technique include the inability to control liposome 





Some of the most important properties for creating liposomes for drug delivery 
include membrane unilamellarity, vesicle size, lipid to drug ratio, and encapsulation 
efficiency [143].  The size of the liposome can play a crucial role in the rate of cellular 
uptake [144].  Vesicle size can be critical when trying to encapsulate large proteins or 
DNA.  A higher encapsulation efficiency corresponds with less waste of the drug product 
and the greater the potential for efficacy.  Current encapsulation efficiencies are at most 
60%, thus finding techniques that achieve values higher than this would be highly 
desirable.  An additional property that is important is especially for large macromolecules 
like DNA is complete encapsulation within the vesicle.  If small portions of the 
molecules are visible from external fluid, they are likely to be damaged and no longer 
therapeutically effective.  As the molecule increases in size and vesicle size decreases, 
the task becomes exponentially more difficult.  
Electrohydrodynamic Atomization 
It is believed that EHDA can be utilized to create liposomes with DNA or protein 
in a self-assembly process, possessing small diameters with narrow size distribution.  The 
benefit is three-fold: (1) EHDA is known to work especially well for DNA;  (2) EHDA 
has been demonstrated to work over a large droplet size range even down to the 
nanometer scale and (3) EHDA can be operated at conditions known to yield near 
monodisperse size distributions.  These last two traits are especially useful attributes of 
the process, as some of the other techniques have little control over the size produced and 




The solvents used included 1-propanol, ethanol, triacetin, Triton® X-100, and 
sodium chloride [NaCl] that were purchased from Sigma-Aldrich (St. Louis, MI).  Egg 
phosphatidylcholine [PC] in a chloroform solution was obtained from Avanti Polar 
Lipids (Alabaster, AL).  DNA plasmid (4kbp) was a generous gift from Valentis, Inc. 
(Burlingame, CA).  The Qunat-iT ™ PicoGreen ® dye kit was purchased from Molecular 




The process envisioned occurs in a single step, creating the lipid bilayer in two 
separate stages.  The first stage includes spraying the encapsulation solution, consisting 
of the macromolecule and lipid, through EHDA.  As the droplet falls towards the catch 
basin, the lipid molecules will self-assemble at the surface of the drop with the 
hydrophobic tails pointing outside of the drop.  The second stage occurs when the drop 
comes in contact with the catch pool.  The catch pool consists of an aqueous solution 
with lipids self-assembled on the surface.  As the drop passes through the surface into the 
pool, a bilayer is created when the lipid layer of the drop pairs with the lipid layer of the 
surface of the pool.  As the drop travels deeper into the pool, the bilayer pinches off 
creating a liposome.  Pautot et al. has published a technique that use a similar idea with 
creating each lipid layer one at a time [145].  However, their technique is done using a 
completely separate method.  They begin by creating a stable inverted emulsion, using 
lipid as a surfactant.  In a second vial, they place a phase-separated fluid with water on 
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the bottom and oil saturated with lipid on top.  At the interface separating the two phases 
is a layer of lipids.  As the first vial is slowly poured on top of the second vial, the denser 
inverted drops will pass through the oil phase and the interface coming to rest in the 
water phase.  As the drop passes through the interface, the second half of the bilayer is 
paired up with the lipid on the inverted drop.  There are many limitations to this process 
that include: creating a stable inverted emulsion, having the drop pass through the lipid 
interface, long diffusion times to set up the lipid at the two phase interface, and the 
tension at the interface is such that only one size distribution of the drop is stable.  Our 
envisioned process avoids these problems by using EHDA to create the primary drop at 
any desirable size, then using velocity and density of the drop to penetrate the lipid 
surface.  Finally, using a catch pool consisting of only water and lipids thus avoiding long 
diffusion times by driving the hydrophobic lipid to the surface of the pool. 
Another lipid encapsulation method using EHDA is Co-extrusion.  This technique 
has the potential to yield similar results [146], but the technique is highly sensitive to 
process variables and conditions.  In contrast, the self-assembly technique presented here 
will be highly robust.  
Phase Diagrams 
The stability of the vesicles formed is highly dependent on the phase stability for 
the initial and final solutions.  Our proof-of-concept study investigated two different 
phase diagrams; the first exploits two fluids and the second exploits a single fluid.  The 
first phase diagram used triacetin, ethanol, water, and the surfactant Tween 80® (Figure 
4.1) [147].  Tween 80® is a nonionic surfactant possessing a hydrophilic head and a 
hydrophobic tail.  Since phosphatidylcholine is a zwitterionic surface-active agent, it was 
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assumed to be chemically similar enough to Tween 80® and the phase diagram would 
vary only slightly with the replacement of the lipid. 
 
Figure 4.1 - Tertiary and tetrahedral phase diagrams, consisting of triacetin, water, Tween 
80 ®, and ethanol.  Diagram reproduced from [147]. 
 
The second proof-of-concept study utilizes PC in different salt solutions.  Exploiting 
these new phase diagrams has helped in the composition of better solutions.  Figure 4.2 
includes two phase diagrams of PC, buffer, and propanol [148, 149]. 
      
Figure 4.2 - Tertiary phase diagrams of 1-propanol and PC. I) includes 0.1 M NaCl 
solution and II) includes water.  The symbols represent:  (L) Liposome suspension 
region, (G) viscous gel phase region, (C) coacervating region, and (S) lipid solution region.  





Using Figure 4.2, the entire two-stage process must traverse from a lipid soluble region 
(of sprayed solution) to a liposome stable solution (once deposited in the catch pool).  
The phase diagram is set up in such a way that the PC concentration is based on the total 
amount of 1-propanol in the system, not the total mass of the system as would be 
expected.  It is also important to note that the objective is to land in the liposome 
suspension region and not the coacervation region.  Coacervation is defined as “the 
separation of a colloidal systems into two liquid phases” [150].  The desire is to end with 
a primarily aqueous solution that would support DNA or protein formulations. 
Procedure 
The first step in creating either the spray or catch solutions was to evaporate the 
chloroform out of lipid solution.  Once the evaporated, alcohol was added into the glass 
vial contained the solidified lipid.  After the lipid is fully soluble in the alcohol solution, 
it can be used to create either the spray or catch solutions.  The spray solution is placed in 
a stainless steel syringe connected by stainless steel tubing to the EHDA.  
The EHDA was custom built and is comprised of a New Era Pump Model NE-1000 
(Farmingdale, NY) and a power supply from Bertan Series 225-30R (Hauppauge, NY).  
The nozzle is a stainless steel capillary with an inner diameter of 1.07 mm and an outer 
diameter of 1.27 mm.  The solution was pumped through the system at a constant flow 
rate with an applied negative voltage.  Drops produced by the EHDA landed in a small 
glass beaker consisting of the catch solution a distance of 7.5 cm below the capillary 
nozzle.  The final solution was then analyzed for size of resulting lipid drops and 
encapsulation efficacy.  
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Triacetin Solutions 
For the triacetin experiments, the composition of the two solutions is tabulated in 
Table 4.1. 
Table 4.1 – Solution composition for triacetin experiments. 
Catch Pool Solution   
 PC Lipid 10 mg 
 Ethanol 0.1 ml 
 Water 100 ml 
Spray Solution   
 PC Lipid 1.25 mg 
 Ethanol 0.181 ml 
 Triacetin 0.728 ml 
 Water 0.09 ml 
 
The spray solution was placed in the syringe and the flow rate of the pump was set to 
0.04 ml/min.  The voltage applied to the system was 2.8 kV in order to obtain a stable 
Taylor Cone flow.  The drops were caught in a small beaker containing 10 ml of catch 
pool solution.   
Salt Solutions 
Creating the spray solution using the salt buffer, propanol, water, and DNA was 
difficult.  Precipitation of the DNA or lipid occurred when the right balance of 
components was not met.  The most stable solution is found in Table 4.2. 
Table 4.2 - Solution composition for salt buffer experiments. 
Catch Pool Solution   
 PC Lipid 0.38 mg 
 Propanol 1.08 ml 
 Water 144 ml 
 NaCl 0.0134 g 
Spray Solution   
 PC Lipid 48 mg 
 Propanol 0.35 ml 
 DNA 0.5 mg 
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 Water 0.563 ml 
 NaCl 5.7 mg 
 
The spray solution was sprayed at different rates in order to create different drop sizes.  
Flow rates ranged from 0.02 ml/min to 0.08 ml/ml.  The voltage applied to the system 
remained constant at 2.3 kV.  The 20 µl of sprayed drops were landed in 10 ml of the 
catch solution.  The catch solution was placed in a small glass beaker, with a stir bar to 
prevent drops from landing on top of each other.  After spraying the solution, samples 
were taken from the catch basin to examine for encapsulation efficiency and liposome 
size.   
Dynamic Light Scattering 
 Lipid particles were sized using dynamic light scattering in a Zeta Sizer (model 
Nano+ ZS, Malvern) with Zetasizer Software v 6.01.  The instrument is able to size 
particles ranging from 1 nanometer to 6 microns.  A 2 ml sample from the solution was 
placed in a plastic cuvette inside the sizer and analyzed for 20 minutes.  Both the starting 
catch and spray solution were tested before spraying to ensure there were no particles 
were in the initial solutions. 
Fluorescent Assay 
 The quantification of encapsulated DNA was determined by a fluorescent assay.  
The assay uses a fluorescent dye, PicoGreen ®, that when bound to double stranded DNA 
strongly fluoresces with an excitation wavelength of 480 nm and an emission wavelength 
of 538 nm.  The Quant-iT™ PicoGreen® kit was purchased and used following the 
manufacturer’s protocol.  Briefly, 100 µl of sample was loaded into a 96 well plate, 
followed by 100 µl of PicoGreen® reagent in TE Buffer.  The sample was incubated for 
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5 minutes at room temperature, in the dark to avoid photobleaching.  Fluorescence values 
for the samples were then analyzed in a SpectraMax Gemini EM spectrofluorometer 
using SoftMax Pro 4.8 software (Molecular Devices, Sunnyvale, CA).  The percent of 
encapsulation was determined by comparing the amount of DNA not encapsulated with 
the total amount of DNA exposed after breaking open the liposomes.  Triton X -100 was 
mixed with the liposome/DNA solution to a concentration of 0.05 % by volume and 
incubated at room temperature for 10 minutes to break open the liposomes. 
 
4.4 Results 
Producing stable triacetin drops is easy, reliable, and robust.  This is due to the 
immiscibility of water in triacetin creating stratified suspensions that are stable over long 
periods of time.  Although triacetin drops are easily formed without the addition of lipid, 
they quickly agglomerate upon settling on the bottom of the beaker.  Using the phase 
diagram, the most stable drops were made in the region that contained a large amount of 
triacetin and a lipid, with a small amount of water (Figure 4.3).  After spraying, the 
triacetin drops slowly decreased in size and were completely dissolved within 12 hours.     
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Figure 4.3 - Solubility and stability results using phosphatidylcholine instead of Tween 
80 ® on the phase diagram.  The dots represent locations of solution solubility.  The 
cross shows locations were the solution is not miscible.  The circled region is the only 
region where it was possible to create stable drops. 
 
Triacetin proved to be a wonderful proof-of-concept material; unfortunately it has limited 
use in DNA delivery.  Macromolecules, such as DNA and proteins, are not soluble in 
triacetin.  Additionally, it is unknown if this process makes liposomes or lipid stabilized 
emulsions because triacetin is not soluble in water.  Therefore, an aqueous based solution 
system was prototyped.   
 Recognizing that salt buffers solve the macromolecule solubility and stability 
problems, our focus shifted to classical buffer constructs.  However, electrospraying is 
difficult and unreliable with purely aqueous solutions.  Adding organic solvents not only 
helps solubilize the lipid, but also can substantially improve the electrospray profile.  
Using up to 40% propanol does not affect DNA stability in solution [151].  It is important 
to notice the PC concentration on the phase diagram in Figure 4.2 II.  Using a PC 
concentration of 5% or below will be soluble in the spray solution, but landing in the 
catch pool will result in coacervation.  For this reason, a 10% or greater concentration of 
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PC has to be used.  During the spray process, the drops were not heavy enough to fully 
penetrate the surface of the catch solution.  Penetration requirements are not well 
understood in literature, but one can imagine that the kinetic energy of the droplet must 
exceed the surface energy of the surface and additionally that the drop be neutrally 
buoyant in the catch pool.  For the sprayed drop, that impact velocity, droplet size, and 
density of the droplet are important.  In addition, the surface tension and density are of 
the catch pool are also critical parameters.  A stir bar was used to lower the surface 
tension of the catch pool and imposed a dynamic condition, which helped the drops 
circulate on the surface and eventually be pulled into the solution.   
The drop size and encapsulation results are shown in Table 4.3 for the three flow 
rates investigated.  The primary drop size does appear to scale with flow rate.  As the 
flow rate increases, so does the drop size.  This fits with the EHDA relation developed by 
Ganan-Calvo [5].  It is interesting to note that the encapsulation efficiency is not 
dependant on drop size and for all velocities is just under 30%. 
Table 4.3 – Results from the salt buffer experiments, drop size and encapsulation 
efficiency.  The error represents one standard deviation. 
 0.08 ml/min 0.04 ml/min 0.02 ml/min 
Encapsulation 28% ± 10 26% ± 0.4 29% ± 7.7 
Primary Drop 
Size (nm) 
1188 ± 1067 973 ± 765 794 ± 182 
Secondary 
Drop Size (nm) 
266 ± 365 92 ± 39 70 ± 33 
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The liposomes produced had two distinct size distributions.  The primary drop is the true 
size produced by the electrospray.  The secondary drop is likely formed from the division 
of the larger vesicles from the surface shear flow created by the stir bar [153].   
The results in Table 4.3 provide the proof-of-concept data required to demonstrate 
the process as a success.  However, a narrow size distribution and increased 
encapsulation efficiency is required to advance the method beyond current limitations.  
We hypothesize that the wide size distribution and low encapsulation efficiency is linked 
to the poor penetration and high shear rates at the catch pool surface.  Thus, a more dense 
solution that fully penetrates the catch solution surface and decreasing the surface tension 
of the catch pool might increase drop penetration.  We are currently exploring methods to 
decrease the catch pool surface tension that include raising the pool temperature to 40oC. 
Final results from these improvements are still pending and potentially outside the scope 
of the work.   
 
4.5 Conclusions 
 Our investigation demonstrates that liposomes can be created using an EHDA 
self-assembly method.  Stable drops are easier to produce when using two immiscible 
fluids.  However, liposomes were created using the salt buffer solution.  The goal of a 
high encapsulation rate was not met; nonetheless a constant encapsulation percentage 
regardless of the liposome size produced is an improvement over other liposome 











The purpose of this study to was to examine EHDA and its potential use in 
pharmaceutical applications.  Each of these chapters built upon one another filling the 
void of information in this area.  EHDA was used on human derived lung cells to test for 
toxicity and immunogenic effects.  Protein atomization was examined and factors 
correlating stability were established.  Finally, a novel method of creating liposomes was 
invented. 
 
EHDA on Human Pulmonary Epithelial Cells 
Our investigations using EHDA on human derived lung cells show electrosprays 
to be a gentle method by which plasmid DNA can be aerosolized without a significant 
loss in native DNA structure.  This study explored the effects of aerosolization of naked 
and complexed plasmid via an electrospray on EpiAirway™ cells that had been cultured 
at an air-liquid interface.  Lactate dehydrogenase released from the cells remained low for 
both the naked and complexed formulations indicating minimal cell toxicity (except for 
the 10:1 PEI/DNA complex).  In addition, cytokine levels (release of interleukin 8) 
appeared nominal and comparable for all conditions, independent of electrospray 
application.  The mild toxicity observed when the tissues were placed in the applied 
electric field was temporary, and the tissues returned to normal within a few hours after 
application.  The experiments were designed to assess the toxicity associated with EHDA 
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sprays; however, future studies would be needed to optimize this approach for 
maximizing transfection.  While future in vivo experiments are required, our results show 
that electrosprays present a promising method for administering DNA-based therapeutics 
to the pulmonary epithelium. 
 
Protein Stability During Aerosolization 
The aerosolization of proteins has had a wide variety of outcomes.  It appears that 
the method of aerosolization is not as important as the properties of the solution and the 
drop size created.  The theory presented in Chapter 3 details how, if the total energy of 
the drop is greater than that of the melting enthalpy, the protein will denature.  The 
experimentally determined transition constant for a variety of proteins was found to be 
around 100. 
SM
dAdH !*100<  
This relation will be incredibly useful for the pharmaceutical industry.  
Formulation and process designers can now take early stage proteins that show 
therapeutic benefits and conduct two simple tests to determine spray-ability.  From those 
tests, the company will know the smallest, therapeutically active drop they can create 
with the solution without denaturing the protein.  To increase confidence in stability, we 
recommend that any protein formulation designer stay sufficiently above the transition 
value of 100 because of the variability seen in the region. 
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Liposome Creation Using EHDA 
Although there are numbers of methods available for creating liposomes, for use 
in gene therapy each method carries unique process and delivery problems.  Chapter 4 
describes a novel process and presents the necessary the proof-of-concept data to 
demonstrate functionality. 
Our investigations demonstrated that liposomes can be created using an EHDA self-
assembly method.  Stable drops are easier to produce when using two immiscible fluids.  
However, liposomes were created using the salt buffer solution.  The goal of a high 
encapsulation rate was not met; nonetheless a consistent encapsulation rate of 20% 
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